Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US EPA approves Byotrol24 as long-lasting virucide

24 May 2023 15:14

RNS Number : 5499A
Byotrol PLC
24 May 2023
 

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

EPA approval for

long-lasting performance against viruses

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to announce that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. 

 

The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). 

The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.

 David Traynor, Executive Director, Byotrol plc comments:

 "This is fantastic news for Byotrol and confirms the excellence of our US surface sanitizers. 

Customers and consumers are now as concerned about protecting against viruses as well as bacteria. This new approval means we can now make specific long-lasting efficacy claims against viruses, which should in turn significantly increase the commercial potential of our US formulations."

 

 

For further information contact:

 

Byotrol Plc

David Traynor, Executive Director

Dr Trevor Francis, Non- Executive Chairman

+44 (0)1925 742 000

Vivan Pinto, Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

byotrol@flagstaffcomms.com

 

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUSASROUUVUAR
Date   Source Headline
5th Sep 20077:01 amRNSDirector/PDMR Shareholding
4th Sep 20077:00 amRNSDirectorate Change
31st Aug 200710:07 amRNSTotal Voting Rights
16th Aug 20078:41 amRNSAIM RULE 26 INFORMATION
6th Aug 20072:49 pmRNSAdditional Listing
1st Aug 20078:21 amRNSTotal Voting Rights
1st Aug 20077:01 amRNSDirector/PDMR Shareholding
30th Jul 20071:04 pmRNSAGM Statement
30th Jul 20077:01 amRNSJoint Venture
20th Jun 20077:01 amRNSAnnual Report and Accounts
8th Jun 20077:00 amRNSAdditional Listing
4th Jun 20077:00 amRNSNEW GLOBAL CONTRACT
4th May 20077:01 amBUSBYOTROL plc • HEALTHCARE PRODUCT LAUNCH
18th Apr 20077:45 amRNSTrading Statement
30th Mar 20079:24 amRNSTotal Voting Rights
22nd Mar 20072:47 pmRNSHolding(s) in Company
19th Mar 20079:56 amRNSHolding(s) in Company
19th Mar 20079:52 amRNSHolding(s) in Company
19th Mar 20079:51 amRNSHolding(s) in Company
19th Mar 20079:49 amRNSHolding(s) in Company
13th Mar 20073:28 pmRNSAdditional Listing
28th Feb 20071:04 pmRNSTotal Voting Rights
23rd Feb 20077:01 amRNSAdditional Listing
21st Feb 20077:01 amRNSDirector/PDMR Shareholding
8th Feb 20073:54 pmRNSAdditional Listing
5th Feb 20072:52 pmRNSHolding(s) in Company
19th Jan 20072:30 pmRNSTotal Voting Rights
12th Jan 20073:07 pmRNSIssue of Equity
14th Dec 20065:00 pmRNSTotal Voting Rights
11th Dec 20067:00 amRNSInterim Results
27th Nov 20069:32 amRNSBoard Appointment
14th Nov 20067:03 amRNSSynergy Healthcare Agreement
1st Nov 20067:01 amRNSIssue of Equity
26th Oct 20061:12 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 20061:02 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200612:28 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200610:24 amRNSDistribution Agreements
16th Oct 20067:01 amBUSByotrol Plc: Result of Byotrol Use in Hospital
18th Sep 200610:56 amBUSREPEAT: Byotrol Plc: Chinese Patent Granted and Customer Orders Shipped
18th Sep 200610:30 amBUSByotrol Plc: Chinese Patent Granted and Customer Orders Shipped
11th Sep 20067:01 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.